Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Committee
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio-Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Application Process
    • The CARB-X Process
    • Official Development Assistance
    • Research Compliance
    • Additional Information and Resources
    • Apply Here
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
    • Media Resources
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Committee
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio-Product Developers
    • CARB-X Graduates
    • Spotlight on Science
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Application Process
    • The CARB-X Process
    • Official Development Assistance
    • Research Compliance
    • Additional Information and Resources
    • Apply Here
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
    • Media Resources
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
GenomeKey

GenomeKey, Bristol, UK
www.genomekey.com

RAPID ID/AST MACHINE LEARNING & WHOLE GENOME
Diagnostic for Sepsis

GenomeKey (Genomic Labs Ltd.) is developing a rapid diagnostic for sepsis by combining novel bacterial DNA extraction techniques, next generation DNA sequencing and machine learning DNA interpretation. With this, GenomeKey seeks to determine the presence of bacteria in a blood sample, identify the bacterial species and determine its antimicrobial susceptibility, all within a matter of hours, at high accuracy. Current clinical diagnostics for infections, such as sepsis, are fundamentally limited by having to grow bacteria. Due to this, it takes 24-72 hours to determine which antibiotics will effectively treat sepsis, and many test samples fail to yield results.

Current Development Stage: Feasibility

CARB-X Investment: Initial investment of up to $3.0m with potential option payments up to $6.5m.

Initial CARB-X Investment Date: January 1, 2021

Carb-X

Led by Boston University

Copyright 2022

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2022